Endogenous expression of Notch pathway molecules in human trabecular meshwork cells.


Journal

Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707

Informations de publication

Date de publication:
03 2022
Historique:
received: 11 11 2021
revised: 23 12 2021
accepted: 05 01 2022
pubmed: 17 1 2022
medline: 5 3 2022
entrez: 16 1 2022
Statut: ppublish

Résumé

Cells in the trabecular meshwork sense and respond to a myriad of physical forces through a process known as mechanotransduction. Whilst the effect of substratum stiffness or stretch on TM cells have been investigated in the context of transforming growth factor (TGF-β), Wnt and YAP/TAZ pathways, the role of Notch signaling, an evolutionarily conserved pathway, recently implicated in mechanotransduction, has not been investigated in trabecular meshwork (TM) cells. Here, we compare the endogenous expression of Notch pathway molecules in TM cells from glaucomatous and non-glaucomatous donors, segmental flow regions, and when subjected to cyclical strain, or grown on hydrogels of varying rigidity. Primary TM from glaucomatous (GTM), non-glaucomatous (NTM) donors, and from segmental flow regions [high flow (HF), low flow (LF)], were utilized between passages 2-6. Cells were (i) plated on tissue culture plastic, (ii) subjected to cyclical strain (6 h and 24 h), or (iii) cultured on 3 kPa and 80 kPa hydrogels. mRNA levels of Notch receptors/ligands/effectors in the TM cells was determined by qRT-PCR. Phagocytosis was determined as a function of substratum stiffness in NTM-HF/LF cells in the presence or absence of 100 nM Dexamethasone treatment. Innate expression of Notch pathway genes were significantly overexpressed in GTM cells with no discernible differences observed between HF/LF cells in either NTM or GTM cells cultured on plastic substrates. With 6 h of cyclical strain, a subset of Notch pathway genes presented with altered expression. Expression of Notch receptors/ligands/receptors/inhibitors progressively declined with increasing stiffness and this correlated with phagocytic ability of NTM cells. Dexamethasone treatment decreased phagocytosis regardless of stiffness or cells isolated from segmental outflow regions. We demonstrate here that the Notch expression in cultured TM cells differ intrinsically between GTM vs NTM, and by substratum cues (cyclical strain and stiffness). Of import, the most apparent differences in gene expression were observed as a function of substratum stiffness which closely followed phagocytic ability of cells. Interestingly, on soft substrates (mimicking normal TM stiffness) Notch expression and phagocytosis was highest, while both expression and phagocytosis was significantly lower on stiffer substrates (mimicking glaucomatous stiffness) regardless of DEX treatment. Such context dependent changes suggest Notch pathway may play differing roles in disease vs homeostasis. Studies focused on understanding the mechanistic role of Notch (if any) in outflow homeostasis are thus warranted.

Identifiants

pubmed: 35033558
pii: S0014-4835(22)00016-1
doi: 10.1016/j.exer.2022.108935
pmc: PMC8885976
mid: NIHMS1774446
pii:
doi:

Substances chimiques

Glucocorticoids 0
RNA, Messenger 0
Receptors, Notch 0
Transcriptional Coactivator with PDZ-Binding Motif Proteins 0
Transforming Growth Factor beta 0
Wnt Proteins 0
YAP-Signaling Proteins 0
Dexamethasone 7S5I7G3JQL

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108935

Subventions

Organisme : NEI NIH HHS
ID : R01 EY030238
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY003279
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY019643
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY016134
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY025721
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY008247
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026048
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Références

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13876-81
pubmed: 25201985
Acta Biomater. 2018 Apr 15;71:444-459
pubmed: 29524673
Nat Cell Biol. 2016 Feb;18(2):168-80
pubmed: 26689676
Curr Pathobiol Rep. 2017 Dec;5(4):323-331
pubmed: 29354328
Invest Ophthalmol Vis Sci. 2011 Apr 05;52(5):2147-52
pubmed: 21220561
Acta Biomater. 2011 Sep;7(9):3302-11
pubmed: 21640206
Sci Rep. 2018 Apr 11;8(1):5848
pubmed: 29643342
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
PLoS One. 2013 Jul 18;8(7):e69113
pubmed: 23874882
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):1-7
pubmed: 15623746
Exp Eye Res. 2009 Jun 15;89(1):95-100
pubmed: 19268465
Exp Eye Res. 2020 Aug;197:108046
pubmed: 32376472
Invest Ophthalmol Vis Sci. 1997 Aug;38(9):1902-7
pubmed: 9286282
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):170-80
pubmed: 24521159
Trends Cell Biol. 2018 Jul;28(7):560-573
pubmed: 29665979
Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3576-85
pubmed: 17652726
Proc Natl Acad Sci U S A. 2019 Dec 5;:
pubmed: 31806762
Stem Cells Int. 2019 Feb 26;2019:5150634
pubmed: 30936923
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1795-802
pubmed: 11431444
Sci Rep. 2020 Jul 2;10(1):10949
pubmed: 32616814
Exp Eye Res. 2009 Apr;88(4):718-23
pubmed: 19071113
J Biol Chem. 2010 Jun 25;285(26):20192-201
pubmed: 20424161
Quant Imaging Med Surg. 2015 Feb;5(1):171-3
pubmed: 25694967
Circ Res. 2005 Mar 18;96(5):567-75
pubmed: 15705961
Front Pharmacol. 2019 Apr 16;10:370
pubmed: 31057403
J R Soc Interface. 2015 Apr 6;12(105):
pubmed: 25740853
Invest Ophthalmol Vis Sci. 2013 Jan 14;54(1):378-86
pubmed: 23258147
J Glaucoma. 2004 Oct;13(5):421-38
pubmed: 15354083
Soft Matter. 2015 Apr 14;11(14):2857-65
pubmed: 25710888
Biochem Biophys Res Commun. 2010 Feb 19;392(4):593-8
pubmed: 20100467
PLoS Biol. 2018 Sep 18;16(9):e2005233
pubmed: 30226866
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):29
pubmed: 33216119
Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1505-13
pubmed: 11381054
J Clin Invest. 2017 Feb 1;127(2):569-582
pubmed: 28067668
Sci Rep. 2020 Sep 24;10(1):15641
pubmed: 32973273
Nat Rev Genet. 2012 Sep;13(9):654-66
pubmed: 22868267
Elife. 2020 Jun 02;9:
pubmed: 32484440
Am J Respir Cell Mol Biol. 2021 Apr;64(4):465-476
pubmed: 33493092
Arch Ophthalmol. 1989 Apr;107(4):572-6
pubmed: 2705927
Oncogene. 2008 Sep 1;27(38):5148-67
pubmed: 18758484
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4809-4817
pubmed: 28973327
J Cell Biol. 2000 Dec 11;151(6):1345-52
pubmed: 11121447
Exp Eye Res. 2008 Feb;86(2):271-81
pubmed: 18155193
Invest Ophthalmol Vis Sci. 2011 Jul 07;52(8):5049-57
pubmed: 21596823
AMA Arch Ophthalmol. 1951 Aug;46(2):113-31
pubmed: 14856471
Development. 2015 Sep 1;142(17):2962-71
pubmed: 26253400
Glia. 2007 Nov 15;55(15):1519-30
pubmed: 17705199
Cancer Res. 2019 May 15;79(10):2697-2708
pubmed: 30898840
Biochim Biophys Acta. 2014 Jun;1843(6):1054-62
pubmed: 24583119
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1164-72
pubmed: 17325160
Invest Ophthalmol Vis Sci. 2012 Aug 09;53(9):5242-50
pubmed: 22786899
Mol Biol Cell. 2006 Sep;17(9):4142-55
pubmed: 16837553
Invest Ophthalmol Vis Sci. 2014 Feb 10;55(2):814-23
pubmed: 24408980
Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1289-96
pubmed: 17395855
Sci Signal. 2013 Dec 03;6(304):ra103
pubmed: 24300895
Curr Biol. 2011 Jan 11;21(1):R40-7
pubmed: 21215938
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):16
pubmed: 33170205
Methods Cell Biol. 2020;156:271-307
pubmed: 32222223
Exp Eye Res. 2006 Apr;82(4):545-57
pubmed: 16386733
Curr Top Dev Biol. 2010;92:73-129
pubmed: 20816393
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):94-101
pubmed: 24401029
Nat Commun. 2017 Nov 20;8(1):1620
pubmed: 29158473
Biomaterials. 2007 Sep;28(27):3944-51
pubmed: 17576010
Dev Cell. 2012 Oct 16;23(4):782-95
pubmed: 23041384
Exp Eye Res. 2017 May;158:3-12
pubmed: 27448987
PLoS One. 2015 Mar 31;10(3):e0122483
pubmed: 25826404
Arch Ophthalmol. 1963 Jun;69:783-801
pubmed: 13949877
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):254-66
pubmed: 24456002
Cell Tissue Res. 2011 Jun;344(3):511-7
pubmed: 21538048
Exp Eye Res. 2020 Jan;190:107888
pubmed: 31786158
Nat Commun. 2017 May 17;8:15206
pubmed: 28513598
Exp Eye Res. 2013 Aug;113:66-73
pubmed: 23727052
Integr Biol (Camb). 2018 Nov 12;10(11):719-726
pubmed: 30328449
Proc Natl Acad Sci U S A. 2018 Apr 17;115(16):E3682-E3691
pubmed: 29610298
J Glaucoma. 2016 Apr;25(4):355-64
pubmed: 25836658
Exp Eye Res. 2015 Jan;130:87-96
pubmed: 25450060
Biomed Opt Express. 2013 Sep 06;4(10):2051-65
pubmed: 24156063
Prog Retin Eye Res. 2021 Jul;83:100917
pubmed: 33217556
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):213-23
pubmed: 24456518
Nat Cell Biol. 2018 Aug;20(8):888-899
pubmed: 30050119
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2857-68
pubmed: 16043860
Exp Eye Res. 2008 Apr;86(4):543-61
pubmed: 18313051
J Cell Sci. 2020 Dec 21;133(24):
pubmed: 33443070
Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):246-259
pubmed: 29340639
Circ Res. 2007 Mar 30;100(6):856-63
pubmed: 17303760
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):41
pubmed: 32832971
Curr Opin Ophthalmol. 2012 Mar;23(2):135-43
pubmed: 22262082
Front Immunol. 2018 Jul 30;9:1744
pubmed: 30105024
Exp Eye Res. 2007 Feb;84(2):275-84
pubmed: 17126833
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1714-1722
pubmed: 30651311
Nat Commun. 2015 Oct 27;6:8528
pubmed: 26503169
Development. 1996 Jul;122(7):2251-9
pubmed: 8681805
Front Immunol. 2018 Jun 01;9:1230
pubmed: 29910816
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):30
pubmed: 32539133
Dev Cell. 2015 Jun 22;33(6):729-36
pubmed: 26051539
Front Microbiol. 2021 Jul 08;12:692832
pubmed: 34305857

Auteurs

Kamesh Dhamodaran (K)

Department of Basic Sciences, College of Optometry, USA.

Hasna Baidouri (H)

Department of Basic Sciences, College of Optometry, USA.

Andrews Nartey (A)

Department of Basic Sciences, College of Optometry, USA.

Julia Staverosky (J)

Casey Eye Institute, Oregon Health and Sciences University, Portland, OR, USA.

Kate Keller (K)

Casey Eye Institute, Oregon Health and Sciences University, Portland, OR, USA.

Ted Acott (T)

Casey Eye Institute, Oregon Health and Sciences University, Portland, OR, USA.

Janice A Vranka (JA)

Casey Eye Institute, Oregon Health and Sciences University, Portland, OR, USA.

Vijay Krishna Raghunathan (VK)

Department of Basic Sciences, College of Optometry, USA; Department of Biomedical Engineering, University of Houston, Houston, TX, USA. Electronic address: vraghunathan@uh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH